



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

JHOTI et al.

Atty. Ref.: 620-374

Serial No. 10/539,447

Group: To be assigned

Filed: June 20, 2005

Examiner: To be assigned

For: SYNTHESIS AND SCREENING OF LIGANDS USING X-RAY CRYSTALLOGRAPHY

\* \* \* \* \*

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

July 11, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
 [within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
 [before Final Office Action or Allowance (requires Rule 97(e)  
 Statement or Rule 17(p) fee)] **N/C**

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
 [before Final Office Action or Allowance (requires Rule 97(e)  
 Statement or Rule 17(p) fee)] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**  
 [after Final Office Action or Allowance (requires Rule 97(e)  
 Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

<b>INFORMATION DISCLOSURE</b>		ATTY. DOCKET NO.	SERIAL NO.			
<b>CITATION</b>		620-374	10/539,447			
APPLICANT						
JHOTI et al.						
(Use several sheets if necessary)		FILING DATE	GROUP			
		June 20, 2005	To be assigned			
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,350,747	02/2002	Glennon et al.			
	5,958,702	09/1999	Benner			
	6,297,021	10/2001	Nienaber et al.			
<b>FOREIGN PATENT DOCUMENTS</b>						
			TRANSLATION			
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 99/15500	04/1999	WIPO				
WO 02/42773	05/2002	WIPO				
WO 00/39585	07/2000	WIPO				
WO 00/00823	01/2000	WIPO				
WO 99/49314	09/1999	WIPO				
WO 97/43232	11/1997	WIPO				
WO 02/20435	03/2002	WIPO				
WO 01/64605	09/2001	WIPO				
EP 1 184 359	03/2002	Europe				
EP 1 130 009	09/2001	Europe				
EP 1 188 769	03/2002	Europe				
WO 99/45389	09/1999	WIPO				
WO 02/077270	10/2002	WIPO				
WO 03/033437	04/2003	WIPO				
WO 03/034071	04/2003	WIPO				
WO 03/086612	10/2003	WIPO				
WO 99/45379	09/1999	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Cousins et al, Chem. Commun., 1999, Vol. 16, pp 1575-1576
	Nguyen et al, Chemical Communications, 2003, Vol. 8, pp 942-943
	Babine et al, Letters in Drug Design & Discovery, 2004, Vol. 1(2), pp 173-177
	Lindstrom, Chemical Reviews, 2002, Vol. 102(8), pp 2751-2771
	Eliseev et al, Chem. Eur. J., 1998, Vol. 4, No. 5, pp 825-834
	Rowan et al, J. Am. Chem. Soc., 1997, Vol. 119, pp 2578-2579
	Ramstrom et al, Nature Reviews Drug Discovery, 2002, Vol. 1, pp 26-36
	Bourne et al, PNAS, 2004, Vol. 101, No. 6, pp 1449-1454
	Choong et al, J. Med. Chem., 2002, Vol. 45, pp 5005-5022

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-374	10/539,447
		APPLICANT	
(Use several sheets if necessary)		JHOTI et al.	
		FILING DATE	GROUP
		June 20, 2005	To be assigned
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)</b>			
	DeLano et al, Science, 2000, Vol. 287, pp 1279-1283		
	Erlanson et al, PNAS, 2000, Vol. 97, No. 17, pp 9367-9372		
	Maly et al, PNAS, 2000, Vol. 97, No. 6, pp 2419-2424		
	Verlinde et al, In Structure-Based Drug Design (Veerapandian, P., ed.), 1997, pp 365-394		
	Verlinde et al, Journal of Computer-Aided Molecular Design, 1992, Vol. 6, pp 131-147		
	Nienaber et al, Nature Biotechnology, 2000, Vol. 18(10), pp 1105-1108		
	Katz et al, Biochemistry, 1995, Vol. 34, pp 8264-8280		
	Katz et al, Nature, 1998, Vol. 391, pp 608-612		
	Bunyapaiboonsri et al, CHEMBIOCHEM, 2001, Vol. 2, pp 438-444		
	Otto et al, Current Opinion in Chemical Biology, 2002, Vol. 6, pp 321-327		
	Lehn et al, Science, 2001, Vol. 291, pp 2331-2332		
	Cousins et al, Current Opinion in Chemical Biology, 2000, Vol. 4, pp 270-279		
	Karan et al, DDT, 2000, Vol. 5, No. 2, pp 67-75		
	Klekota et al, Trends Biotechnol., 1999, Vol. 17, pp 205-209		
	Lehn, Chem. Eur. J., 1999, Vol. 5, No. 9, pp 2455-2463		
	Ganesan, Angew. Chem. Int. Ed. 1998, Vol. 37, No. 20, pp 2828-2831		
	Otto et al, DDT, 2002, Vol. 7, No. 2, pp 117-125		
	Berl et al, Chem. Eur. J., 2000, Vol. 6, No. 11, pp 1938-1946		
	Berl et al, Eur. J. Org. Chem., 1999, pp 3089-3094		
	Brady et al, Chem. Commun., 1996, pp 319-320		
	Erlanson et al, Nature Biotechnology, 2003, Vol. 21, pp 308-314		
	Congreve et al, Angew. Chem. Int. Ed., 2003, Vol. 42(37), pp 4479-4482		
	Eksterowicz et al, Journal of Molecular Graphics and Modelling, 2002, Vol. 20, pp 469-477		
	Carr et al, DDT, 2002, Vol. 7, No. 9, pp 522-527		
	Nguyen et al, Angew. Chem. Int. Ed., 2001, Vol. 40, No. 9, pp 1774-1776		
	Lewis et al, Angew. Chem. Int. Ed., 2002, Vol. 41, No. 6, pp 1053-1057		
	Huc et al, Combinatorial Chemistry & High Throughput Screening, 2001, pp 109-130		
	Huc et al, Eur. J. Inorg. Chem., 1999, pp 1415-1420		
	Huc et al, Proc. Natl. Acad. Sci., 1997, Vol. 94, pp 2106-2110		
	Hochgurtel et al, PNAS, 2002, Vol. 99, No. 6, pp 3382-3387		
	Greer et al, Journal of Medicinal Chemistry, 1994, Vol. 37, No. 8, pp 1035-1054		
	Bramson et al, J. Med. Chem., 2001, Vol. 44, pp 4339-4358		
	Blundell et al, Nature Reviews Drug Discovery, 2002, Vol. 1, pp 45-54		
*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)